Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Novel Study Designs in Precision Medicine – Basket, Umbrella and Platform Trials

Author(s): Renju Ravi and Harshad V. Kesari*

Volume 17, Issue 2, 2022

Published on: 16 March, 2021

Page: [114 - 121] Pages: 8

DOI: 10.2174/1574884716666210316114157

Price: $65

Abstract

The concept of ‘one size fits all’ - one treatment for patients with a particular disease, seems to be outdated. The advent of precision medicine has prompted profound changes in clinical research and it allows researchers to predict more accurately, the prevention and treatment strategies for a specific disease population. Novel study designs are, therefore, essential to establish safe and effective personalized medicine. Basket, umbrella and platform trial designs (collectively referred to as master protocols) are biomarker enrichment designs that allow for testing more than one hypotheses within a protocol, thus accelerating drug development. These trial designs tailor intervention strategies based on patient’s risk factor(s) that can help predict whether they will respond to a specific treatment. Basket trials evaluate therapy for various diseases that share a common molecular alteration, while umbrella trials evaluate multiple targeted therapies for a single disease that is stratified into subgroups based on different molecular alterations/ risk factors. These designs are complex and their major limitations stem from the fact that it would be inappropriate to completely replace histological typing with molecular profiling alone. However, in the upcoming decades, these trial designs are likely to gain popularity and improve the efficiency of clinical research. This article briefly overviews the characteristics of master protocol designs with examples of completed and ongoing clinical trials utilizing these study designs.

Keywords: Precision medicine initiative, biomarker enrichment designs, master protocols, oncology trials, drug development, pharmacogenomic models.

« Previous Next »
Graphical Abstract

[1]
Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging 2016; 6(6): 310-27.: 18.
[2]
Saad ED, Paoletti X, Burzykowski T, Buyse M. Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol 2017; 14(5): 317-23.
[http://dx.doi.org/10.1038/nrclinonc.2017.8] [PMID: 28169302]
[3]
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372(9): 793-5.
[http://dx.doi.org/10.1056/NEJMp1500523] [PMID: 25635347]
[4]
Major Initiatives | DCTD. 2020. Available at: https://dctd.cancer.gov/majorinitiatives/NCI-sponsored_trials_in_precision_ medicine.htm.
[5]
Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015; 33(9): 975-7.
[http://dx.doi.org/10.1200/JCO.2014.59.8433] [PMID: 25667288]
[6]
Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 2006; 24(1): 64-9.
[http://dx.doi.org/10.1200/JCO.2005.02.5825] [PMID: 16382114]
[7]
Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26(26): 4253-60.
[http://dx.doi.org/10.1200/JCO.2007.15.0672] [PMID: 18779612]
[8]
Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019; 20(1): 572.
[http://dx.doi.org/10.1186/s13063-019-3664-1] [PMID: 31533793]
[9]
Master protocols. Efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry (Draft guidance). Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf].
[10]
Berry SM, Connor JT, Lewis RJ. The platform trial: An efficient strategy for evaluating multiple treatments. JAMA 2015; 313(16): 1619-20.
[http://dx.doi.org/10.1001/jama.2015.2316] [PMID: 25799162]
[11]
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04488081.
[12]
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02735707
[13]
ISRCTN - ISRCTN86534580: PRINCIPLE: A trial evaluating treatments for suspected COVID-19 in people aged 50 years and above with pre-existing conditions and those aged 65 years and above. 2020. Available at: http://www.isrctn.com/ISRCTN 86534580
[14]
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373(8): 726-36.
[http://dx.doi.org/10.1056/NEJMoa1502309] [PMID: 26287849]
[15]
West HJ. Novel precision medicine trial designs: Umbrellas and baskets. JAMA Oncol 2017; 3(3): 423.
[http://dx.doi.org/10.1001/jamaoncol.2016.5299] [PMID: 27930754]
[16]
Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015; 21(7): 1514-24.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3473] [PMID: 25680375]
[17]
Simon R. New designs for basket clinical trials in oncology. J Biopharm Stat 2018; 28(2): 245-55.
[http://dx.doi.org/10.1080/10543406.2017.1372779] [PMID: 28877003]
[18]
Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017; 102(6): 934-41.
[http://dx.doi.org/10.1002/cpt.814] [PMID: 28795401]
[19]
Abrams J, Conley B, Mooney M, et al. National cancer institute’s precision medicine initiatives for the new national clinical trials network. Am Soc Clin Oncol Educ Book 2014; 34: 71-6.
[http://dx.doi.org/10.14694/EdBook_AM.2014.34.71] [PMID: 24857062]
[20]
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377(1): 62-70.
[http://dx.doi.org/10.1056/NEJMra1510062] [PMID: 28679092]
[21]
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1. 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT02034981.
[22]
Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008; 14(9): 2717-25.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-4575] [PMID: 18451237]
[23]
Govindan R, Mandrekar SJ, Gerber DE, et al. ALCHEMIST trials: A golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin Cancer Res 2015; 21(24): 5439-44.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0354] [PMID: 26672084]
[24]
Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP) — a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015; 21(7): 1514-24.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3473] [PMID: 25680375]
[25]
Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: The LUNG-MAP study. Clin Pharmacol Ther 2015; 97(5): 488-91.
[http://dx.doi.org/10.1002/cpt.88] [PMID: 25676724]
[26]
Protocols | FOCUS4. 2019. Available at: http://www.focus4 trial.org/centres/protocols/.
[27]
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86(1): 97-100.
[http://dx.doi.org/10.1038/clpt.2009.68] [PMID: 19440188]
[28]
Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16(13): 1324-34.
[http://dx.doi.org/10.1016/S1470-2045(15)00188-6] [PMID: 26342236]
[29]
Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 2017; 15(1): 134.
[http://dx.doi.org/10.1186/s12916-017-0902-9] [PMID: 28728605]
[30]
Strzebonska K, Waligora M. Umbrella and basket trials in oncology: Ethical challenges. BMC Med Ethics 2019; 20(1): 58.
[http://dx.doi.org/10.1186/s12910-019-0395-5] [PMID: 31443704]
[31]
Renfro LA, Sargent DJ. Statistical controversies in clinical research: Basket trials, umbrella trials, and other master protocols: A review and examples. Ann Oncol 2017; 28(1): 34-43.
[http://dx.doi.org/10.1093/annonc/mdw413] [PMID: 28177494]

Rights & Permissions Print Cite
Article Metrics
80
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy